De-risk Development and Manufacture of Bispecific Antibodies with Lonza

In this executive summary you'll discover why we are the CDMO to turn to when you want a faster path to First in Human trials. Leveraging more than three decades of expertise and innovative technologies, we provide an integrated drug substance, drug product program and can deliver 13 months* from DNA to CMC, IND or IMPD filing for bsAbs. To help you find any adverse safety issues before you make potentially costly mistakes when scaling up to GMP production, you can also have TOX drug substance for testing in just seven months if you want it.